MGI PHARMA (MOGN) Updates Phase 2 Interim Results from Study of Glidel Wafer
More News related to MOGN
- S&P Announces Changes to U.S. Index
- MGI PHARMA (MOGN) sNDA for Aloxi Capsules Accepted for Review By the FDA
- MGI PHARMA (MOGN) Said Aquavan NDA Accepted for Review by FDA
- Unusual 11 Mid-Day Movers: MBIA, PMI Higher; Celegene Lower on Clinical Results (MBI, PMI, CELG)
- Notable Analyst Rating Changes: CC, GMST, FL Up; EMR, PALM, MOGN Down
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
MGI PHARMA, INC. (Nasdaq: MOGN) summarized interim results from a phase 2 combination study of Gliadel Wafer (polifeprosan 20 with carmustine implant) in patients with newly-diagnosed, resectable, high grade malignant gliomas presented at the 2006 Society for Neuro-Oncology (SNO) Annual Meeting. Interim data from 35 patients with this aggressive brain tumor showed a median survival of 18.6 months when Gliadel Wafer and temozolomide are used in combination with surgery and radiotherapy.
Gliadel Wafer is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in newly diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. Gliadel Wafer is also indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. Gliadel Wafer is the only FDA approved brain cancer treatment capable of providing localized delivery of chemotherapy directly to the site of the tumor. Up to eight Gliadel wafers can be implanted in the resection cavity after a tumor is surgically removed.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
